Neil Gregory Almstead Ptc Therapeutics, Inc. (PTCT) insider trading activity

Neil Gregory Almstead is CHIEF TECHNICAL OPS OFFICER of PTC THERAPEUTICS, INC.. Currently has a direct ownership of 100,625 shares of PTCT, which is worth approximately $7.58 Million. The most recent transaction as insider was on Nov 25, 2025, when has been sold 71,928 shares (Common Stock) at a price of $83.89 per share, resulting in proceeds of $6,034,039. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 101K

0.27% 3M change

16.73% 12M change

Total Value Held $7.58 Million

Neil Gregory Almstead Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 25 2025	SELL Open market or private sale	$6,034,039 $83.89 p/Share	71,928 Reduced 41.68%	100,625 Common Stock
Nov 25 2025	BUY Exercise of conversion of derivative security	$1,943,494 $27.02 p/Share	71,928 Added 39.1%	112,024 Common Stock
Nov 24 2025	SELL Open market or private sale	$2,851,451 $80.16 p/Share	35,572 Reduced 26.12%	100,625 Common Stock
Nov 24 2025	BUY Exercise of conversion of derivative security	$961,155 $27.02 p/Share	35,572 Added 25.0%	106,726 Common Stock
Oct 03 2025	SELL Open market or private sale	$3,650,350 $66.37 p/Share	55,000 Reduced 35.34%	100,625 Common Stock
Oct 03 2025	BUY Exercise of conversion of derivative security	$1,697,300 $30.86 p/Share	55,000 Added 26.55%	152,183 Common Stock
Feb 20 2025	SELL Open market or private sale	$79,089 $50.12 p/Share	1,578 Reduced 1.55%	100,353 Common Stock

Feb 19 2025	SELL Open market or private sale	$65,130 $50.1 p/Share	1,300 Reduced 1.26%	101,931 Common Stock
Jan 08 2025	SELL Open market or private sale	$69,064 $44.5 p/Share	1,552 Reduced 1.48%	103,231 Common Stock
Jan 07 2025	SELL Open market or private sale	$57,355 $45.34 p/Share	1,265 Reduced 1.19%	104,783 Common Stock
Jan 03 2025	BUY Grant, award, or other acquisition	-	19,000 Added 15.19%	106,048 Common Stock
Dec 02 2024	SELL Open market or private sale	$3,638,856 $52.32 p/Share	69,550 Reduced 44.65%	86,202 Common Stock
Dec 02 2024	BUY Exercise of conversion of derivative security	$3,547,050 $51.0 p/Share	69,550 Added 31.23%	153,158 Common Stock
Feb 15 2024	BUY Grant, award, or other acquisition	-	25,000 Added 22.48%	86,202 Common Stock
Jan 30 2024	SELL Open market or private sale	$16,840 $27.25 p/Share	618 Reduced 1.0%	61,202 Common Stock
Jan 09 2024	SELL Open market or private sale	$44,124 $29.01 p/Share	1,521 Reduced 2.4%	61,820 Common Stock
Jan 08 2024	SELL Open market or private sale	$35,399 $28.64 p/Share	1,236 Reduced 1.91%	63,341 Common Stock
Jan 31 2023	SELL Open market or private sale	$28,746 $45.63 p/Share	630 Reduced 0.98%	63,949 Common Stock
Jan 11 2023	SELL Open market or private sale	$16,989 $44.36 p/Share	383 Reduced 0.59%	64,579 Common Stock
Jan 10 2023	SELL Open market or private sale	$20,305 $42.93 p/Share	473 Reduced 0.72%	64,962 Common Stock
Jan 09 2023	SELL Open market or private sale	$29,828 $41.66 p/Share	716 Reduced 1.08%	65,435 Common Stock
Jan 05 2023	BUY Grant, award, or other acquisition	-	17,000 Added 20.44%	66,151 Common Stock
Feb 01 2022	SELL Open market or private sale	$24,200 $40.0 p/Share	605 Reduced 1.22%	48,853 Common Stock
Jan 07 2022	SELL Open market or private sale	$29,121 $38.52 p/Share	756 Reduced 2.11%	35,058 Common Stock
Jan 07 2022	BUY Grant, award, or other acquisition	-	14,400 Added 22.55%	49,458 Common Stock

NGA

Neil Gregory Almstead

CHIEF TECHNICAL OPS OFFICER

South Plainfield, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PTCT shares.

Notify only if

Value

Insider Trading

Get notified when an Ptc Therapeutics, Inc. insider buys or sells PTCT shares.

Notify only if

Operation

Value

Type

News

Receive news related to PTC THERAPEUTICS, INC.

Track Activities on PTCT

Account